Furthermore, the combination of cabozantinib and erlotinib demonstrated substantially increased anti-tumor activity over either agent administered alone in a MET-amplified NSCLC xenograft model resistant to EGFR inhibition. This evidence concerns the gene MET and non-small cell lung carcinoma.